Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAILOR-PANC
2025-522431-34-00Phase 2Authorised
- Sponsor
- Capital Region of Denmark
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of olaparib, erlotinib, crizotinib, oxaliplatin, trametinib and 15 more in pancreatic cancer (PC) (2 arms), sponsored by Capital Region of Denmark. Primary endpoint: Progression-free survival. Planned start May 2026; status: authorised.
02
Drugs
olapariberlotinibcrizotiniboxaliplatintrametinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2025-522431-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522431-34-00.